Table 2 MGFA PIS and MGSTI at last follow up
From: Outcome measures and treatment effectiveness in late onset myasthenia gravis
MGFA-PIS | ||||||||
Type of MG | CSR/ MM-0 | MM-1 | MM-2 | MM-3 | PR | Symptomatic | Total | |
Ocular | 4 (11,1%) | 6 (16,7%) | 9 (25%) | 3 (8,3%) | 13 (36,1%) | 1 (2,8%) | 36 | |
EOMG | 1 (2,5%) | 5 (12,5%) | 1 (2,5%) | 15 (37,5%) | 16 (42,5%) | 2 (5%) | 40 | |
LOMG | 3 (4,2%) | 5 (6,9%) | 5 (6,9%) | 23 (31,9%) | 32 (45,8%) | 4 (5,6%) | 72 | |
Thymoma | 1 (4,0%) | 1 (4,0%) | – | 7 (28%) | 13 (52%) | 3 (12%) | 25 | |
Sieronegative | 1 (4,8%) | 5 (23,8%) | 3 (14,3%) | 5 (23,8%) | 7 (33,3%) | - | 21 | |
Anti-MUSK | - | 2 (14,3%) | - | 1 (7,1%) | 9 (64,2%) | 2 (9,5%) | 14 | |
Total | 10 (4,8%) | 24 (11,5%) | 18 (8,7%) | 54 (26%) | 90 (44,2%) | 12 (5,8%) | 208 | |
MGSTI | ||||||||
Type of MG | 0 | 1 | 2 | 3 | 4 | 5 | 6 | Total |
Ocular | 16 (44,4%) | 9 (25%) | 9 (25%) | 1 (2,8%) | 1 (2,8%) | 36 | ||
EOMG | 2 (5,0%) | 7 (17,5%) | 16 (40%) | 13 (32,5%) | 2 (5,0%) | 40 | ||
LOMG | 11 (15,3%) | 20 (27,8%) | 26 (36,1%) | 11 (15,3%) | 1 (1,4%) | 2 (2,8%) | 1 (1,4%) | 72 |
Thymoma | 1 (4,0%) | 7 (28,0%) | 13 (52,0%) | 1 (4,0%) | 2 (8,0%) | 1 (4,0%) | 25 | |
Sieronegative | 7 (30,4%) | 3 (13,0%) | 6 (26,1%) | 4 (17,4%) | 23 | |||
Anti-MUSK | 2 (14,3%) | 8 (57,1%) | 2 (14,3%) | 2 (14,3%) | 14 | |||
Total | 37 (17,9%) | 48 (23,2%) | 78 (37,5%) | 32 (15,5) | 2 (1,0%) | 8 (3,9%) | 2 (1,0%) | 208 |